CyrilC.LlamosoMD

PubMed

• 4 citations
  Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicista...
  Katy Moore, Nilay Thakkar, Mindy Magee, Heather Sevinsky, Blisse Vakkalagadda, Susan Lubin, Cyril Llamoso, Peter Ackerman> ;Antimicrobial Agents and Chemotherapy. 2022 Apr 19
• 2 citations
  Evaluation of the pharmacokinetic drug-drug interaction between the antiretroviral agents fostemsavir and maraviroc: a single-sequence crossover study in healthy parti...
  Mary Beth Wire, Mindy Magee, Peter Ackerman, Cyril Llamoso, Katy Moore> ;HIV Research & Clinical Practice. 2021 Dec 9
• 9 citations
  Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV ...
  Margaret Gartland, Eric Arnoult, Brian T. Foley, Max Lataillade, Peter Ackerman, Cyril Llamoso, Mark Krystal> ;The Journal of Antimicrobial Chemotherapy. 2021 Oct 11
• 4 citations
  Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Temsavir, the Active Moiety of Fostemsavir.
  Mindy Magee, Jill Slater, Frank Mannino, Peter Ackerman, Cyril Llamoso, Katy H. P. Moore> ;Journal of Clinical Pharmacology. 2021 Jul 1
• 3 citations
  Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals
  Sarah-Jane Anderson, Miranda Murray, David Cella, Robert M. Grossberg, Debbie Hagins, William J. Towner, Marcia Wang, Andrew Clark, Amy Pierce, Cyril Llamoso, Peter Ac...> ;The Patient. 2021 Jun 28
• 10 citations
  Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1.
  Peter Ackerman, Melanie Thompson, Jean-Michel Molina, Judith A. Aberg, Isabel Cassetti, Michael J. Kozal, Antonella Castagna, Marcelo Martins, Moti Ramgopal, Eduardo S...> ;AIDS. 2021 Jun 1
• 9 citations
  Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense® Entry assay.
  Margaret Gartland, Nannan Zhou, Eugene L. Stewart, Amy Pierce, Andrew Clark, Peter Ackerman, Cyril Llamoso, Max Lataillade, Mark Krystal> ;The Journal of Antimicrobial Chemotherapy. 2021 Feb 11
• 47 citations
  Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study
  Max Lataillade, Jacob Lalezari, Michael J. Kozal, Judith A. Aberg, Gilles Pialoux, Pedro Cahn, Melanie Thompson, Jean-Michel Molina, Santiago Moreno, Beatriz Grinsztej...> ;The Lancet. HIV. 2020 Nov 1
• 13 citations
  Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure–Response Analysis
  Chakradhar V. Lagishetty, Katy H. P. Moore, Peter Ackerman, Cyril Llamoso, Mindy Magee> ;Clinical and Translational Science. 2020 Mar 19
• 9 citations
  Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative p...
  Katy P Moore, Mindy Magee, Heather Sevinsky, Ming Chang, Susan Lubin, Elsa Myers, Peter Ackerman, Cyril Llamoso> ;British Journal of Clinical Pharmacology. 2019 Jun 5
• 26 citations
  Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HI...
  Javier Morales-Ramirez, Johannes R. Bogner, Jean-Michel Molina, Johan Lombaard, Ira B. Dicker, David A. Stock, Michelle DeGrosky, Margaret Gartland, Teodora Pene Dumit...> ;Plos One. 2018 Oct 23
• 2 citations
  Large-scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B.
  Chang Wook Kim, Chang Seop Kim, Hee Yeon Kim, Chang Don Lee, Kyungha Yu, Cyril Llamoso, Heon Ju Lee> ;The Korean Journal of Internal Medicine. 2018 Jan 1
• 58 citations
  Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study.
  Fabien Zoulim, Giampiero Carosi, Susan Greenbloom, Włodzimierz Mazur, T. Nguyen, Lennox J. Jeffers, Maurizia Rossana Brunetto, Song Yu, Cyril Llamoso> ;Journal of Hepatology. 2015 Jan 1
• 115 citations
  Efficacy of Entecavir With or Without Tenofovir Disoproxil Fumarate for Nucleos(t)ide-Naive Patients With Chronic Hepatitis B
  Anna S. Lok, Huy N. Trinh, Giampiero Carosi, Ulus Salih Akarca, Adrián Gadano, François Habersetzer, William Sievert, David Wong, Meghan Lovegren, David Cohen, Cyril L...> ;Gastroenterology. 2012 Sep 1
• 23 citations
  Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B...
  Guangbi Yao, Chengwei Chen, Weilun Lu, Hong Ren, Deming Tan, Yuming Wang, Daozheng Xu, Jessica Liu, Dong Xu, Cyril Llamoso> ;Hepatology International. 2008 Aug 30
• Join now to see all

Journal Articles

• Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection  
  Michael Kozal, Edwin Dejesus, Cyril Llamoso, The New England Journal of Medicine